Tilray is a global leader in medical cannabis research and production dedicated to providing safe, consistent and reliable therapy to patients. We are first GMP-certified medical cannabis producer to supply cannabis flower and extract products to thousands of patients, physicians, pharmacies, hospitals, governments and researchers on four continents.



Tilray's experience is unmatched worldwide. Our team of 130+ professionals on the ground in 5 countries serves thousands of patients around the globe. Our $26 million cultivation facility is among the most advanced in the world.


Tilray is the first GMP-certified medical cannabis producer to supply cannabis flower and extracts. All of our products are produced with meticulous care to ensure the highest quality, consistency and purity for our patients.



We are committed to scientific research that leads to an improved quality of life for patients in a time frame that matters. We are partnering with leading hospitals and universities to advance the clinical applications of cannabinoids.



Tilray takes tremendous pride in our customer service, patient outreach, and physician interaction. We recognize the importance of tracking potential adverse events as well as therapeutic benefits in order to ensure the safety of our patients.

Precisely formulated PRODUCTS

Tilray cultivates a wide range of strains to meet patient needs including indicas, sativas, hybrids, and CBD-rich varieties. Tilray medical cannabis is available in two primary forms: extracts and dried flower. Each can be administered or consumed via a variety of methods. Tilray is working closely with patients, physicians, and regulators to provide consistent availability of a range of compliant and effective forms of medical cannabis.


For the therapeutic value and risks of cannabinoid-based medicines to be fully understood, Tilray believes it is critical to evolve current scientific understanding of the field. Our clinical research program is designed with that in mind. We understand the importance of developing well-characterized, consistent preparations of specific cannabinoid compositions that meet regulatory agencies’ standards for use in clinical research.



Tilray choreographs a complex series of cutting-edge processes spanning fourteen weeks to deliver an unparalleled medical cannabis product to its patients. From cultivation to final shipping, Tilray's team brings precision, professionalism and care to each stage of the process.

Our aspiration is to build the world’s most trusted and admired medical cannabis brand. As laws and regulations governing medical cannabis evolve in different jurisdictions, we are actively seeking to expand our operations to serve patients in need.


In September 2016, Tilray became the first company to legally export medical cannabis products from North America to Australia for research and compassionate access purposes. In 2017, the company will ship additional products to Australia and expand distribution to New Zealand.  


In 2014, Tilray began operating in Canada. Today, Tilray is the leading provider of high quality medical cannabis in the country, supplying thousands of patients in every province with consistent access to whole flower, milled blends and oils.



In June 2016, Tilray became the first company to legally export medical cannabis products from North America to Europe. In 2017, Tilray is expanding distribution of its products to new countries in Europe. 


In February 2017, Tilray announced a strategic agreement  to distribute Tilray products in Chile and Brazil.

Tilray's diverse management team of industry-leading experts includes PhD research scientists, master horticulturists, engineers, and patient advocates. Click on members of management to see their bios.